RxDoctor Payments Data

Gina Viser

Family · Bolivar, MONPI 1316495492

Payments from drug & device makers

$9,325in general payments, 2019–2025

Across 500 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$859
  • AstraZeneca$848
  • Novartis$551
  • Merck$497
  • Lilly USA, LLC$419
  • Pfizer$372
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$8,58892%
  • Education$7378%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie50$859
AstraZeneca46$848
Novartis32$551
Merck27$497
Lilly USA, LLC20$419
Pfizer26$372
Takeda Pharmaceuticals U.S.A., Inc.18$355
Daiichi Sankyo Inc.12$352
Bristol Myers Squibb21$333
Johnson & Johnson18$331
GSK24$323
Gilead(2 entities)12$322
Seagen Inc.3$277
Novo Nordisk17$255
Sanofi10$212
Genentech USA, Inc.9$164
Sobi, Inc4$143
Eisai Inc.7$133
Jazz Pharmaceuticals Inc.6$133
Bayer8$121
Regeneron Healthcare Solutions, Inc.5$119
Boehringer Ingelheim8$118
Caris MPI, Inc.4$104
Stemline Therapeutics Inc.6$102
Karyopharm Therapeutics Inc.4$100
Amgen7$99
AVEO Pharmaceuticals, Inc.5$96
Dendreon Pharmaceuticals LLC4$88
Otsuka America Pharmaceutical, Inc.5$85
Abbott4$74
Taiho Oncology, Inc.4$67
E.r. Squibb & Sons, L.L.C.4$65
Astellas Pharma US Inc3$63
Incyte Corporation4$62
Pharmacosmos Therapeutics Inc.3$57
Idorsia Pharmaceuticals US Inc3$55
Sanofi-aventis U.S. LLC2$54
Collegium Pharmaceutical, Inc.4$54
Rigel Pharmaceuticals, Inc.3$52
Teva Pharmaceuticals USA, Inc.4$52
Array Biopharma Inc2$48
Organon4$44
Servier Pharmaceuticals LLC2$43
Biohaven Pharmaceuticals, Inc.3$42
Genmab U.S., Inc.2$41
Adaptive Biotechnologies Corporation1$40
Springworks Therapeutics, Inc.2$39
Exelixis Inc.2$38
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$33
Beone Medicines USA, Inc.2$33
Blueprint Medicines Corporation1$30
Amarin Pharma, Inc.2$27
Dexcom, Inc.2$26
Biohaven Pharmaceutical Holding Company Ltd.2$25
EMD Serono, Inc.1$21
Coherus Oncology, Inc.1$21
Avanir Pharmaceuticals, Inc.1$20
Corcept Therapeutics1$20
Iovance Biotherapeutics, Inc.1$19
Indivior Inc.1$16

How this compares

$9,325 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$2,299
Medicare patients
19
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$37,007
TrulicityDulaglutide15$14,402
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$13,330
JardianceEmpagliflozin14$13,251
LinzessLinaclotide14$10,048
Combivent RespimatIpratropium/Albuterol Sulfate20$9,566
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$7,931
EliquisApixaban14$7,321
XareltoRivaroxaban11$6,278
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$1,497
Albuterol Sulfate HfaAlbuterol Sulfate65$1,286
Ventolin HfaAlbuterol Sulfate23$1,270
Clobetasol Propionate15$742
Famotidine39$730
Levothyroxine Sodium92$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$323$44,93963 claims
Boehringer IngelheimJardiance, Combivent Respimat$118$22,81734 claims
Lilly USA, LLCTrulicity$419$14,40215 claims
AstraZenecaBreztri Aerosphere$848$13,33019 claims
AbbVieLinzess$859$10,04814 claims
PfizerEliquis$372$7,32114 claims
Johnson & JohnsonXarelto$331$6,27811 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$52$16116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Bolivar

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →